Annals of Surgical Oncology

, Volume 21, Issue 2, pp 700–700 | Cite as

Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’”

Breast Oncology
  • 538 Downloads

Keywords

Public Health Breast Cancer Carcinoma Lymph Node Oncol 

To the Editors:

We agree with Chao and Han that uncertainty exists about the cytokeratins recognized by the CAM5.2 antibody in immunohistochemistry.1,2 It has become clear from immunoblot experiments that CAM5.2 is specific for cytokeratin 8 and to a lesser extent for the closely related cytokeratin 7, but not for cytokeratin 18.3,4 Nevertheless, CAM5.2 is generally accepted to be suitable for detection of metastatic breast cancer in (sentinel) lymph nodes because almost all breast carcinomas also strongly express cytokeratin 7.

Notes

Conflict of interest

None

References

  1. 1.
    Koolen BB, Valdés Olmos RA, Wesseling J, et al. Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Chao WR, Han CP. Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on “early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla.” Ann Surg Oncol. (in press).Google Scholar
  3. 3.
    Makin CA, Bobrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984;37:975–83.PubMedCrossRefGoogle Scholar
  4. 4.

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  1. 1.Department of Nuclear MedicineNetherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  2. 2.Department of Surgical OncologyNetherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  3. 3.Department of PathologyNetherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands

Personalised recommendations